KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBT Margin (2017 - 2026)

Amneal Pharmaceuticals has reported EBT Margin over the past 9 years, most recently at 6.78% for Q4 2025.

  • For Q4 2025, EBT Margin rose 888.0% year-over-year to 6.78%; the TTM value through Dec 2025 reached 4.61%, up 658.0%, while the annual FY2025 figure was 4.61%, 658.0% up from the prior year.
  • EBT Margin for Q4 2025 was 6.78% at Amneal Pharmaceuticals, up from 0.67% in the prior quarter.
  • Over five years, EBT Margin peaked at 7.14% in Q2 2025 and troughed at 41.61% in Q2 2022.
  • A 5-year average of 1.74% and a median of 0.01% in 2022 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: plummeted -4812bps in 2022 and later soared 4656bps in 2023.
  • Year by year, EBT Margin stood at 3.04% in 2021, then soared by 59bps to 1.26% in 2022, then tumbled by -978bps to 13.53% in 2023, then soared by 84bps to 2.1% in 2024, then skyrocketed by 423bps to 6.78% in 2025.
  • Business Quant data shows EBT Margin for AMRX at 6.78% in Q4 2025, 0.67% in Q3 2025, and 7.14% in Q2 2025.